ENDV (ENDONOVO THERAPEUTICS)
NEW LOW-FLOAT
ENDV (Endonovo Therapeutics, Inc
ENDV is a Biotech company developing non-invasive, bio-electromagnetic products with anti-inflammatory properties designed to promote regeneration in damaged tissue and organs in animals and humans WITHOUT the use of Stem-Cells.
ENDV - TREATING DISEASES WITHOUT STEM CELL INJECTIONS
Endonovo Therapeutics, Inc. is a biotechnology company developing off-the-shelf regenerative products that no longer require the injection of stem cells.
The company's first platform, Cell Free Therapeutics, harnesses the biological secretions of cells to create therapies that can be immediately administered following injuries or to treat acute and chronic diseases.
Thier second platform is the development of non-invasive, bioelectronics to stimulate the body's natural repair system to treat injuries and inflammatory diseases.
The basis for ENDV's Time-Varying Electromagnetic Field (TVEMF) technology was created at NASA in conjunction with the development of cell therapies to treat injuries and diseases that astronauts might encounter during long term manned missions in outer space.
The original concept was developed when NASA realized that cellular growth increased as the space shuttle crossed the earth’s magnetic poles. It took over eight years to define and develop a device that produced the same effect. This magnetic field device (TVEMF) was originally designed to enhance cellular expansion (growth) in NASA’s rotating wall bioreactor. After numerous experimental studies, the results were so significant with the bioreactor that a prototype was designed for use directly on the human body.
ENDV's Cell Free Therapeutics represents the next generation of regenerative products that may be able to mitigate many of the drawbacks of stem cell transplants.
The potential advantages of Cell Free Therapeutics, include:
•Truly “off-the-shelf” therapies that could be administered immediately for strokes or a heart attacks
•Scalable production leading to affordability of products compared to cell therapies
•Simpler to manufacture, store and transport in comparison to cell therapies
•Better quality control of products in comparison to cell therapies
•Stimulate endogenous repair system
•Less risk of adverse immunological responses (immunogenicity)
•Less risk or tumorigenicity
